
    
      PRIMARY OBJECTIVES: I. To evaluate the 6-month progression-free survival in patients with
      recurrent or progressive high grade gliomas treated with ritonavir and lopinavir. SECONDARY
      OBJECTIVES: I. To evaluate the toxicity of ritonavir and lopinavir in this patient
      population. OUTLINE: Patients receive oral ritonavir and lopinavir twice daily in the absence
      of disease progression or unacceptable toxicity. After completion of study therapy, patients
      are followed periodically.
    
  